Imatinib is the first tyrosine kinase inhibitor to be marketed and used to treat chronic myeloid leukemia (CML) by targeting the oncogenic protein BCR-ABL. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.